Amplifon S.p.A. AMP.MI
Composite 42/100; the shares have moved about 45% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 26/100 — a moderate mark against it.
Valuation ranks 58/100 — a slight point in its favour.
Growth ranks 26/100 — a moderate mark against it. Balance-sheet strength ranks 34/100 — a moderate mark against it. Quality ranks 42/100 — a slight mark against it.
What the company does Amplifon S.p.A. (AMP.MI) distributes hearing solutions and customized products across Europe, the Middle East, Africa, the Americas, and Asia Pacific. Its Ampli-care platform and Amplifon App enhance audiological care and device management. The company offers hearing devices like Ampli-power and Ampli-mini, serving a growing global market.
Key financials Amplifon’s profitability metrics show mixed signals: ROE 6%, ROA 4%, and ROCE 9%, with net margins at 3%. Revenue declined -1% and EPS fell -68% year-over-year. Debt/Equity stands at 1.67x, and interest coverage is 3.51x, while the current ratio is 0.48.
Stock health Momentum is weak: -41% over 12 months, -26% from its 52-week high, and RSI(14) at 69 (overbought). The Piotroski F-Score is 5/9, and Altman Z-score is 1.55, indicating moderate financial distress risk.
Price vs fair value The stock trades at a **PREMIUM of 18.70%** to our fair-value estimate of 9.42 and a **discount of 12.60%** to the 12-month target of 13.05. - Valuation percentile 64/100 (highest pillar) suggests fair value perception. - Forward P/E of 13.39 vs trailing 36.23 signals earnings recovery expectations. - Gross margin 24% and FCF yield 11% support premium pricing. - Weak growth (-1% revenue, -68% EPS) and high payout ratio (95%) limit upside.
Looking forward Analysts expect a rebound in earnings (forward P/E 13.39), but weak growth and high leverage (Debt/EBITDA 4.26x) remain concerns. Momentum trends and profitability metrics suggest caution until growth stabilizes.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.